This post is also available in:
English
London, UK, 9 September 2021 – Avillion LLP, a drug development company focused on the co-development and financing of pharmaceutical candidates, has announced positive high-level results from the MANDALA and DENALI Phase III trials of a new, fixed-dose combination inhaler for those who suffer from asthma.
JoinAStudy.ca Investigators Dr. Syed Anees, Dr. Peter Dzongowski, Dr. Anil Gupta, Dr. Sam Henein and Dr. Sean Peterson all participated in this trial and played an important role in presenting findings that indicate the treatment in question (a combination of albuterol and budesonide) contributed to clinically meaningful reductions in the risk of severe flare-ups (exacerbations) as compared to treatment with albuterol on its own.
People diagnosed with asthma experience symptoms such as breathlessness and wheezing, which may vary over time in severity and frequency depending on the seriousness of the attack. These attacks may become quite severe regardless of an individual’s compliance with their treatment or overall control of their condition.
“Severe asthma exacerbations are a significant burden for many asthma patients of all ages resulting in impaired quality of life, hospitalization, treatment with systemic corticosteroids which can lead to serious side effects, and the possibility of premature death. Many millions of patients globally rely on their rescue inhaler to alleviate acute symptoms, but this does not treat the underlying inflammation in asthma. The MANDALA and DENALI trials demonstrate an albuterol/budesonide rescue inhaler can address inflammation and prevent exacerbations, making PT027 an important potential new treatment option for patients,” said Bradley E. Chipps, a past President of the American College of Allergy, Asthma & Immunology and Medical Director of Capital Allergy & Respiratory Disease Center in Sacramento, USA.
You can read the full press release on Avillion’s website here.